Awards Nomination 20+ Million Readerbase
Indexed In
  • Academic Journals Database
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Scimago
  • Ulrich's Periodicals Directory
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
Share This Page
Evaluation of ZOSTAVAX? via the intradermal route using the MicronJet?
4th International Conference on Vaccines & Vaccination
September 24-26, 2014 Valencia Convention Centre, Spain

Brian K Meyer, Chan Beals, Yotam Levin and Robert K Evans

Scientific Tracks Abstracts: J Vaccines Vaccin

Abstract:

H ere we report the results of intradermal vaccination studies that were performed with an attenuated virus (varicella; ZOSTAVAX?). Intradermal vaccination using the MicronJet? by Nanopass Technologies was compared to the current route of administration (subcutaneous). It was demonstrated with ZOSTAVAX? that doses of 1/3 rd and 1/10 th , the full dose elicited both antibody and T-cell responses that were equivalent to a full dose delivered subcutaneously. A full dose of ZOSTAVAX? administered intradermally resulted in a higher overall antibody titer when compared to the subcutaneous route.

Biography :

Brian K Meyer is a Principal Scientist in Bioprocess Research and Development, Merck Research Laboratories. He completed his PhD at The Pennsylvania State University. He has held various positions at Merck, both in the research and manufacturing divisions.